LAURUSLABS Laurus Labs Q1 FY26 results (Apr–Jun 2025) and concall
Laurus Labs delivered a strong Q1 FY26 performance with robust revenue growth of 31% YoY to ₹1,570 crores, driven by healthy CDMO and formulations demand. Profitability saw significant improvement with gross margins at 59.5% and EBITDA margins at 25%. The company is making strategic investments in capacity expansion, including a large fermentation facility in Vizag, while maintaining a healthy debt profile.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 1,185 | 1,265 | 1,650 | 1,433 |
| EBITDA | 182 | 206 | 395 | 327 |
| Net profit | 42 | 57 | 252 | 158 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
